Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer
Simona Nanni, … , Alfredo Pontecorvi, Antonella Farsetti
Simona Nanni, … , Alfredo Pontecorvi, Antonella Farsetti
Published July 15, 2002
Citation Information: J Clin Invest. 2002;110(2):219-227. https://doi.org/10.1172/JCI15552.
View: Text | PDF
Article Genetics

Signaling through estrogen receptors modulates telomerase activity in human prostate cancer

  • Text
  • PDF
Abstract

Research Article

Authors

Simona Nanni, Michela Narducci, Linda Della Pietra, Fabiola Moretti, Annalisa Grasselli, Piero De Carli, Ada Sacchi, Alfredo Pontecorvi, Antonella Farsetti

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
Effect of the selective aromatase inhibitor letrozole on the interaction...
Effect of the selective aromatase inhibitor letrozole on the interaction between ERs and the hTERT-ERE and on telomerase activity. (a) LNCaP cells were cultured for 16 hours in the absence (lanes 2 and 3) or the presence of E2 (10–7 M, lanes 4 and 5) or T (10–7 M) (lanes 6–9) with (lanes 3, 5, and 9) or without the nonsteroidal aromatase inhibitor letrozole (1 μM) added 1 hour before hormone addition. Nuclear extracts (5 μg) were then prepared and incubated with a 32P-labeled oligonucleotide encompassing the proximal hTERT-ERE. Reaction in the presence of anti-AR (αAR) or anti–ER-β (αERβ) Ab’s are shown in lanes 7 and 8, respectively. Lane 1 corresponds to probe incubated without nuclear extracts. Migration of a slower migrating complex is indicated (arrow). (b) Extracts (0.1 μg) from LNCaP cells treated for 4 hours with R1881 (10–8 M) or T (10–7 M) with or without the nonsteroidal aromatase inhibitor letrozole (1 μM) added 1 hour before ligand addition were assayed for telomerase activity by TRAP.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts